Prediction of sarcopenia using a battery of circulating biomarkers

Abstract Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary diseases (COPD). However, the effective circulating biomarkers to accurately diagnose and assess sarcopenia are not...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rizwan Qaisar, Asima Karim, Tahir Muhammad, Islam Shah, Javaidullah Khan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f5e4387fc83b452b905f09f981cae09a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f5e4387fc83b452b905f09f981cae09a
record_format	dspace
spelling	oai:doaj.org-article:f5e4387fc83b452b905f09f981cae09a2021-12-02T17:33:00ZPrediction of sarcopenia using a battery of circulating biomarkers10.1038/s41598-021-87974-62045-2322https://doaj.org/article/f5e4387fc83b452b905f09f981cae09a2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87974-6https://doaj.org/toc/2045-2322Abstract Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary diseases (COPD). However, the effective circulating biomarkers to accurately diagnose and assess sarcopenia are not known. We recruited male healthy controls and patients with CHF and COPD (n = 81–87/group), aged 55–74 years. Sarcopenia was clinically identified based on hand-grip strength, appendicular skeletal muscle index and physical capacity as recommended by the European working group for sarcopenia. The serum levels of amino-terminal pro-peptide of type-III procollagen, c-terminal agrin fragment-22, osteonectin, irisin, fatty acid-binding protein-3 and macrophage migration inhibitory factor were significantly different between healthy controls and patients with CHF and COPD. Risk scores for individual biomarkers were calculated by logistic regressions and combined into a cumulative risk score. The median cutoff value of 3.86 was used to divide subjects into high- and low-risk groups for sarcopenia with the area under the curve of 0.793 (95% CI = 0.738–0.845, p < 0.001). A significantly higher incidence of clinical sarcopenia was found in high-risk group. Taken together, the battery of biomarkers can be an effective tool in the early diagnosis and assessment of sarcopenia.Rizwan QaisarAsima KarimTahir MuhammadIslam ShahJavaidullah KhanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rizwan Qaisar Asima Karim Tahir Muhammad Islam Shah Javaidullah Khan Prediction of sarcopenia using a battery of circulating biomarkers
description	Abstract Loss of muscle mass and strength with aging, termed sarcopenia is accelerated in several comorbidities including chronic heart failure (CHF) and chronic obstructive pulmonary diseases (COPD). However, the effective circulating biomarkers to accurately diagnose and assess sarcopenia are not known. We recruited male healthy controls and patients with CHF and COPD (n = 81–87/group), aged 55–74 years. Sarcopenia was clinically identified based on hand-grip strength, appendicular skeletal muscle index and physical capacity as recommended by the European working group for sarcopenia. The serum levels of amino-terminal pro-peptide of type-III procollagen, c-terminal agrin fragment-22, osteonectin, irisin, fatty acid-binding protein-3 and macrophage migration inhibitory factor were significantly different between healthy controls and patients with CHF and COPD. Risk scores for individual biomarkers were calculated by logistic regressions and combined into a cumulative risk score. The median cutoff value of 3.86 was used to divide subjects into high- and low-risk groups for sarcopenia with the area under the curve of 0.793 (95% CI = 0.738–0.845, p < 0.001). A significantly higher incidence of clinical sarcopenia was found in high-risk group. Taken together, the battery of biomarkers can be an effective tool in the early diagnosis and assessment of sarcopenia.
format	article
author	Rizwan Qaisar Asima Karim Tahir Muhammad Islam Shah Javaidullah Khan
author_facet	Rizwan Qaisar Asima Karim Tahir Muhammad Islam Shah Javaidullah Khan
author_sort	Rizwan Qaisar
title	Prediction of sarcopenia using a battery of circulating biomarkers
title_short	Prediction of sarcopenia using a battery of circulating biomarkers
title_full	Prediction of sarcopenia using a battery of circulating biomarkers
title_fullStr	Prediction of sarcopenia using a battery of circulating biomarkers
title_full_unstemmed	Prediction of sarcopenia using a battery of circulating biomarkers
title_sort	prediction of sarcopenia using a battery of circulating biomarkers
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f5e4387fc83b452b905f09f981cae09a
work_keys_str_mv	AT rizwanqaisar predictionofsarcopeniausingabatteryofcirculatingbiomarkers AT asimakarim predictionofsarcopeniausingabatteryofcirculatingbiomarkers AT tahirmuhammad predictionofsarcopeniausingabatteryofcirculatingbiomarkers AT islamshah predictionofsarcopeniausingabatteryofcirculatingbiomarkers AT javaidullahkhan predictionofsarcopeniausingabatteryofcirculatingbiomarkers
_version_	1718380098654044160

Prediction of sarcopenia using a battery of circulating biomarkers

Ejemplares similares